Últimas noticias sobre GeneDx Holdings (NASDAQ:WGS) Bolsa

GeneDx Holdings

GeneDx Hldgs

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

LFCR

SPSC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: WGS, LFCR, SPSC, RGP y UDR.

5 acciones en el foco este viernes: WGS, LFCR, SPSC, RGP y UDR

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings Corp

RBC Capital analyst Maurice Choy maintains Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) with a Outperform and lowers the price target from C$65 to C$62.

Price Target

Analyst Ratings

TSX:PPL

RBC Capital Maintains Outperform on Pembina Pipeline, Lowers Price Target to C$62

Compass Point analyst Ed Engel upgrades Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from Sell to Neutral.

Upgrades

COIN

Compass Point Upgrades Coinbase Global to Neutral

WIIM

INHD

INNO HOLDINGS shares are trading higher after the company announced a strategic cooperation with New Life Technology Development on developing a B2B marketplace platform.

RBC Capital analyst Andrew Wong maintains Nutrien (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NTR#TSX">NTR</a>) with a Outperform and raises the price target from C$60 to C$65.

TSX:NTR

RBC Capital Maintains Outperform on Nutrien, Raises Price Target to C$65

RBC Capital analyst Andrew Wong maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Outperform and raises the price target from $60 to $65.

RBC Capital Maintains Outperform on Nutrien, Raises Price Target to $65

RBC Capital analyst Maurice Choy reiterates Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Outperform and maintains C$67 price target.

Reiteration

TSX:ENB

RBC Capital Reiterates Outperform on Enbridge, Maintains C$67 Price Target

RBC Capital analyst Maurice Choy reiterates Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) with a Outperform and maintains $67 price target.

RBC Capital Reiterates Outperform on Enbridge, Maintains $67 Price Target

Lantronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) reported in-line earnings for the third quarter, <a href="https://www.benzinga.com/quote/LTRX/earnings">after the closing bell on Thursday</a>.
The company posted quarterly earnings of 3 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $28.50 million which missed the analyst consensus estimate of $29.12 million.
&#8220;We&#8217;re positioning Lantronix to lead the next wave of industrial and enterprise transformation at the edge,&#8221; said Saleel Awsare, president and CEO of Lantronix. &#8220;This quarter reflects continued investment in high-growth areas — from AI-enabled gateways to 5G connectivity — while advancing our innovation roadmap, global partnerships and talent base.&#8221;
Lantronix said it sees fourth-quarter adjusted EPS of $0.00-$0.02, versus market estimates of $0.05 Est, and expects sales of $26.50 million-$30.580 million versus expectations of $30.13 million.
Lantronix shares fell 1.4% to trade at $2.07 on Monday.
These analysts made changes to their price targets on Lantronix following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Ryan Koontz maintained Lantronix with a Buy and lowered the price target from $5.5 to $4.5.</li>
<li>Canaccord Genuity analyst George Gianarikas maintained the stock with a Buy and lowered the price target from $4.5 to $3.</li>
</ul>
Considering buying LTRX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-1024x593.png" alt="" class="wp-image-912121" style="width:542px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45348276/marriott-international-to-rally-more-than-17-here-are-10-top-analyst-forecasts-for-monday">Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

LTRX

These Analysts Cut Their Forecasts On Lantronix Following Q3 Results

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-1024x683.jpeg" alt="" class="wp-image-12776" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Pharma Panic That Could Pay Us</h2>
Executive orders often move markets before move policy is implemented.&nbsp;Late Sunday, President Trump said he'll sign a Most‑Favored‑Nation (MFN) order forcing U.S. payers to match the&nbsp;lowest&nbsp;price any country gets for each prescription drug. Asian investors heard that and immediately slammed Japanese pharma stocks 5‑7 %. If the pattern holds, U.S.‑listed drug makers will open in the red when Wall Street rings the bell.
My read:&nbsp;a&nbsp;knee‑jerk sell‑off would be a gift. The MFN idea died in the courts four years ago and may take months to resurface in enforceable form. Meanwhile, global manufacturers have an obvious counter‑move: pull supply from the handful of ultra‑cheap markets (looking at you, Czech Republic) and re‑launch everywhere at a single, slightly discounted list price. Net revenue changes little; headline risk does all the damage.
Below are the two ways I plan to monetize that dislocation.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company&nbsp;A – Platform Cash&nbsp;Machine With Royalty Armor</h3>
<ul class="wp-block-list">
<li>Fundamentals 
<ul class="wp-block-list">
<li>Piotroski F‑Score&nbsp;9 / 9&nbsp;– pristine balance sheet, rising margins, no accounting red flags.</li>
<li>FY‑24 royalty revenue&nbsp;+27 %&nbsp;y/y; operating cash‑flow margin&nbsp;45 %.</li>
<li>Net debt:&nbsp;$‑170 M&nbsp;(yes, net cash) after another quarter of buybacks.</li>
</ul>
</li>
<li>Technicals 
<ul class="wp-block-list">
<li>Price has stair‑stepped higher since October.&nbsp;</li>
<li>Price is above both 50 and 200 day moving averages&nbsp;– a textbook rising channel.</li>
</ul>
</li>
<li>Why MFN risk is minimal 
<ul class="wp-block-list">
<li>Company&nbsp;A doesn't set list prices; its drug‑delivery platform earns a&nbsp;mid‑single‑digit royalty on&nbsp;net&nbsp;sales&nbsp;paid by its partners.</li>
<li>Those partners are market behemoths—Johnson &amp; Johnson, Inc. (JNJ), Bristol Myers Squibb Company (BMY), Pfizer, Inc. (PFE)—that can afford to yank products from low‑margin jurisdictions until pricing equilibrates.</li>
</ul>
</li>
<li>How I'm playing it 
<ul class="wp-block-list">
<li>Bull‑put credit spread: Taking advantage of expensive puts to collect a net credit which we&#8217;ll get to keep if the stock doesn&#8217;t fall further over the next few months.</li>
<li>Equity kicker: Allocate part of that credit to Jan&nbsp;2026&nbsp;OTM calls. Theta from the spread finances the lottery ticket.</li>
</ul>
</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company&nbsp;B – The Diabetes Moon‑Shot</h3>
This one is a pure speculative bet—but with asymmetric payoff.
<ul class="wp-block-list">
<li>Catalyst 
<ul class="wp-block-list">
<li>First‑in‑human trial just made its debut participant&nbsp;insulin‑independent after 30&nbsp;years of Type‑1 Diabetes. Not only doesn&#8217;t he need to take insulin, but he doesn&#8217;t need to take any immunosuppressant drugs either. No safety issues so far.&nbsp;</li>
</ul>
</li>
<li>Balance sheet 
<ul class="wp-block-list">
<li>~$800 M cash against a ~$400 M annual burn → roughly&nbsp;24&nbsp;months of runway&nbsp;with zero debt.</li>
</ul>
</li>
<li>Risk 
<ul class="wp-block-list">
<li>Biology can always surprise.</li>
<li>FDA hurdles, capital raises if share price pops.</li>
</ul>
</li>
<li>Position sizing 
<ul class="wp-block-list">
<li>Treat as a&nbsp;lotto ticket: less than 1% of portfolio in common shares—small enough to torch without blinking, big enough to matter if the therapy works.</li>
</ul>
</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Why I Like The Pair Trade</h3>
<ul class="wp-block-list">
<li>Company&nbsp;A&nbsp;offers steady cash flow, strong technical momentum, and optionality via a low‑cost spread strategy.</li>
<li>Company&nbsp;B&nbsp;is binary, but the upside—an outright cure for T1D—is hard to overstate.</li>
<li>Both should rebound once the MFN headlines fade and investors remember revenue isn't set by social media posts.</li>
</ul>
I have trades&nbsp;teed up&nbsp;for both names. If you'd like to know the tickers and get an alert the moment I pull the trigger, feel free to subscribe to my trading Substack/occasional email list below.&nbsp;
And if you&#8217;d rather limit your risk here, you can download the Portfolio Armor app by&nbsp;aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-1024x683.jpeg" alt="" class="wp-image-12777" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to <a href="https://portfolioarmor.substack.com/">our trading Substack</a> using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2.jpg" alt="" class="wp-image-12778" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Biotech

Equities

Opinion

Profiting From A Pharma Panic

EverCommerce Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) reported better-than-expected first-quarter sales results, after the <a href="https://www.benzinga.com/quote/evcm/earnings">closing bell on Thursday.</a>
EverCommerce reported quarterly earnings of 1 cent per share which missed the analyst consensus estimate of 3 cents per share. The company reported quarterly sales of $142.27 million which beat the analyst consensus estimate of $139.57 million.
&#8220;EverCommerce&#8217;s first quarter results exceeded the top end of our guidance range for both Revenue and Adjusted EBITDA, driven by strong execution and continued active cost management,&#8221; said Eric Remer, EverCommerce&#8217;s Founder and CEO. &#8220;We continue to make solid progress with implementing our transformation and optimization initiatives, which include strategic investments in high margin areas of business such as payments monetization as well as artificial intelligence.&#8221;
EverCommerce said it sees second-quarter sales of $144.500 million to $147.500 million, versus market estimates of $145.93 million.
EverCommerce shares gained 2.4% to trade at $11.26 on Monday.
These analysts made changes to their price targets on EverCommerce following earnings announcement.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst David Hynes maintained EverCommerce with a Buy and raised the price target from $13 to $14.</li>
<li>Barclays analyst Ryan Macwilliams maintained the stock with an Equal-Weight rating and raised the price target from $9 to $11.</li>
</ul>
Considering buying EVCM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-1024x592.png" alt="" class="wp-image-912140" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12114659/image-130.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45348276/marriott-international-to-rally-more-than-17-here-are-10-top-analyst-forecasts-for-monday">Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

EVCM

EverCommerce Analysts Raise Their Forecasts After Upbeat Sales

RBC Capital analyst Brad Erickson reiterates CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Outperform and maintains $42 price target.

CARG

RBC Capital Reiterates Outperform on CarGurus, Maintains $42 Price Target

Scotiabank analyst Nicholas Yulico maintains Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) with a Sector Perform and raises the price target from $18 to $19.

SBRA

Scotiabank Maintains Sector Perform on Sabra Health Care REIT, Raises Price Target to $19

Inno Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 206.3%

Scotiabank analyst Greg Harrison maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Sector Outperform and lowers the price target from $52 to $51.

RCKT

Scotiabank Maintains Sector Outperform on Rocket Pharmaceuticals, Lowers Price Target to $51

RBC Capital analyst Nelson Ng maintains Algonquin Power (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AQN#TSX">AQN</a>) with a Sector Perform and raises the price target from C$5.5 to C$6.

TSX:AQN

RBC Capital Maintains Sector Perform on Algonquin Power, Raises Price Target to C$6

RBC Capital analyst Nelson Ng maintains Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) with a Sector Perform and raises the price target from $5.5 to $6.

RBC Capital Maintains Sector Perform on Algonquin Power, Raises Price Target to $6

AMC Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) on Friday reported a decline <a href="https://www.benzinga.com/quote/AMCX/earnings">in first-quarter sales.</a>
The company witnessed "continued pressure to core revenue streams," according to JPMorgan.&nbsp;
The AMC Networks Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5a281c52adcfa70001367bf2/david-karnovsky">Analyst David Karnovsky</a> maintained an Underweight rating, while reducing the price target from $8 to $6.
The AMC Networks Thesis: The company reported revenues and AOI (adjusted operating income) at $555 million and $104 million, missing estimates of $569 million and $108 million, respectively, Karnovsky said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
AMC Networks' domestic advertising declined by 15% in the quarter, which was not only worse than expected but also marked an acceleration from the 12% decline reported in the previous quarter, he added.
While reiterating their 2025 guidance, management indicated that there was "no noticeable impact on advertising from a macro perspective," while pointing to softness on the digital side, the analyst stated.
"The company was optimistic on streaming growth for the rest of the year which is reflective of benefits from rate increases, new series, and improved user engagement," he further wrote.
AMCX Price Action: Shares of AMC Networks had declined by 5.7% to $5.96 at the time of publication on Monday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44019170/steve-madden-faces-looming-margin-pressure-and-tariff-headwinds-analyst-predicts-tough-road-ahead"> AMC Networks Does Not Gain Subscribers In Q1 And Profit Falls, Stock Slides</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings Misses

Movers

AMCX

AMC Networks' Sales Drop As Analyst Warns Of 'Continued Pressure' On Revenue

Last week brought more &#8216;wait and see&#8217; from the FED. The central bank held rates as expected, citing the economy&#8217;s strength and attributing any recent indicator anomalies to tariff-induced swings in net exports.
The Fed&#8217;s stance fortified the US dollar, which reclaimed the key psychological level of 100 on the Dollar Index. It also helped support a rally in risk assets like stocks, which erased April&#8217;s decline entirely. The news also drove Asian currency moves, as the Japanese yen weakened late in the week. Risk-off mode drove investors into other currencies, notably the British pound.
The week ahead is relatively light on <a href="https://singaporeforexclub.com/how-to-read-the-forex-economic-calendar">news</a>, but those few items are impactful enough to make a big difference. Tuesday will bring the latest CPI news for the US dollar, while Australian unemployment and British GDP projections mark the second part of the week, alongside the latest US retail sales numbers. Powell&#8217;s speech on Thursday will provide additional clarification on the <a href="https://singaporeforexclub.com/macroeconomic-indicators-in-forex-trading">FED&#8217;s policy</a>, and any deviations from the tone set last Wednesday could drive volatility.
<h2 class="wp-block-heading">Key News:</h2>
<ul class="wp-block-list">
<li>Tuesday:&nbsp;USD— CPI, GBP—Governor Bailey Speech</li>
<li>Wednesday: AUD—Wage Price Index</li>
<li>Thursday: AUD—Unemployment, GBP—GDP, USD—Retail Sales, PPI, Powell Speech</li>
</ul>
<h2 class="wp-block-heading">Pairs In Focus</h2>
<h3 class="wp-block-heading">1. GBP SGD</h3>
GBP/SGD found a clear footing, forming a double bottom and failing to break to a lower low after a higher high in late April.
The level to look for is 1.73780 on the daily chart, about 100 pips above where the price closed on Friday.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="460" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123222/GBPSGD_2025-05-11_22-08-24-1024x460.png" alt="" class="wp-image-12804" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123222/GBPSGD_2025-05-11_22-08-24-1024x460.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123222/GBPSGD_2025-05-11_22-08-24-300x135.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123222/GBPSGD_2025-05-11_22-08-24-768x345.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123222/GBPSGD_2025-05-11_22-08-24.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
GBP/SGD Daily Chart, Source: TradingView
If support at 1.71530 holds, a sustained push higher could take out the previous highs around 1.76.
<h3 class="wp-block-heading">2. CHF JPY</h3>
This pair has been forming a bullish pennant pattern on the daily chart, with a key level around 174.100, which is the middle of the formation.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="456" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123231/CHFJPY_2025-05-11_22-10-26-1024x456.png" alt="" class="wp-image-12805" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123231/CHFJPY_2025-05-11_22-10-26-1024x456.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123231/CHFJPY_2025-05-11_22-10-26-300x134.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123231/CHFJPY_2025-05-11_22-10-26-768x342.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12123231/CHFJPY_2025-05-11_22-10-26.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
CHF/JPY Daily Chart, Source: TradingView
As long as price holds above this level on the daily chart, the price action should be bullish. It has the potential to take out the previous month&#8217;s high around 176.500 and move toward 177.400, around 250 <a href="https://singaporeforexclub.com/forex-pip-value-per-lot-size">pips</a> from current levels. Retail sentiment is 69% short, adding to the contrarian trade potential.
<h3 class="wp-block-heading">Notes:</h3>
<ul class="wp-block-list">
<li>AUD/NZD: Continues gaining bullish momentum. 1.09 is the level above the market to watch for.</li>
<li>AUD CAD: Remains in a ranging motion after fully erasing April's decline. The key support is around 0.88750, while resistance sits at 0.89750.</li>
<li>AUD/CHF: It is forming a bearish flag, with a possible support around 0.52800.</li>
<li>AUD/SGD: Saw a minor pullback higher, but it looks ready to continue the bearish momentum. Key resistance to watch is 0.84250.</li>
<li>AUD/JPY:&nbsp; Continues to retrace the significant decline from March. The key resistance level above the market is at 95.230.</li>
<li>CAD/JPY: After a fakeout lower, it recovered losses toward the end of the week. To clarify further bullish movement, it has to close above 105.</li>
<li>EUR/AUD: Tested the support below the market around 1.74300 but failed to break it. This level remains the key for further downside movement.</li>
<li>EUR JPY: Remains within the established support and resistance zone between 163.850 and 161.135.</li>
<li>EUR NZD: It stayed flat for the week and shows signs of further ranging price action.</li>
<li>GBP AUD: Pulled back higher, but ran into an intermediate resistance around 2.0600.</li>
<li>GBP NZD: Reversed after dipping early in the week, but closed below the key level of 2.25200.</li>
<li>NZD/JPY: The pair closed the week flat, but the overall bias is bullish, with a potential target of 87.330.</li>
</ul>
Note: Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. <a href="https://singaporeforexclub.com/">Singapore Forex Club</a> is not responsible for any financial decisions based on this article&#8217;s contents. Readers may use this data for information and educational purposes only.

Forex

Risk-Off Mode Could Spur Further Yen Decline

<a href="https://www.cnmv.es/webservices/verdocumento/ver?t=%7Bb75ee6db-df80-49ee-bf19-dfb0c0eed666%7D" title="https://www.cnmv.es/webservices/verdocumento/ver?t=%7Bb75ee6db-df80-49ee-bf19-dfb0c0eed666%7D">https://www.cnmv.es/webservices/verdocumento/ver?t=%7Bb75ee6db-df80-49ee-bf19-dfb0c0eed666%7D</a>

Guidance

Global

General

GRFS

Grifols Q1 Revenue €1.786 Billion; Adjusted EBITDA €400 Million; Q1 Net Income €60 Million; Confirms 2025 Guidance; Says On Track To Launch Fibrinogen In Europe In Q4'25 And In The U.S. In H1'26, Following FDA Approval; Expects To Share Greater Detail In 2025 Due To Impact Of Inflation Reduction Act On Its Financial Results

Scotiabank analyst Greg McGinniss maintains Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Sector Perform and lowers the price target from $39 to $37.

REXR

Scotiabank Maintains Sector Perform on Rexford Industrial Realty, Lowers Price Target to $37

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting

GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

GeneDx Announces Completion of Fabric Genomics Acquisition

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

GeneDx Holdings

Noticias

Últimas noticias sobre GeneDx Holdings (NASDAQ:WGS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL